There’s no one “right” modeling or simulation approach—but some are better suited to answer or explore specific types of questions.
Beyond Disease Labels
Bridging Autoimmune Modeling and ML-enabled Precision Medicine
Oral Absorption DDI Assessment Using PBPK, AI & Regulatory Perspective
Oral absorption-mediated drug-drug interactions (DDIs) are important in drug development.
Advancing NAMS with Quantitative Systems Toxicology and Microphysiological Systems
Quantitative systems toxicology (QST) is a proven method for translating in vitro inputs to toxicity predictions
Improving PBBM with Surface pH Driven Dissolution: Case Studies for Palbociclib and Ibuprofen
Dissolution rate of ionizable compounds is historically treated in a simplified manner based on the solubility of the drug in bulk intestinal fluid at a static pH
You Don’t Have to Trust an AI Agent Blindly
How Composer keeps AI-enabled MIDD workflows scientific and under your control
QSP Modeling to Support Development of Ziftomenib Combinations in Acute Myeloid Leukemia
Ziftomenib is a potent, selective, oral menin inhibitor that is U.S. FDA-approved as monotherapy at 600mg QD for adults with relapsed/refractory (R/R) NPM1-m AML and no other satisfactory treatments.
Using Many In Vitro Assay Systems to Make a Kidney Toxicity Prediction of Doxorubicin: A Proof of Concept in Support of the New Approach Methodologies Initiative
With the introduction of the new approach methodologies (NAMs) initiative, there is a focus on finding alternatives to animal studies to validate a drug’s safety before administering in humans.
PBPK in Drug Development and Regulatory Decision-Making: Past, Present, and Future
The Journey of PBPK M&S Applications in Drug Development and Regulatory Submissions
Physiologically based Biopharmaceutics Modeling (PBBM) Reveals a Low Dissolution-related Bioequivalence Risk for Immediate-Release Amlodipine Tablets
A conservative BCS class III classification was recently proposed for amlodipine based on inconclusive permeability evidence.
Complementing QSP with Machine Learning to Predict IGA-Based Population Response in an Atopic Dermatitis Model
Atopic Dermatitis (AD) is a chronic skin condition characterized by inflammation, itching, and redness. AD is an active area of drug development, with 120+ drug candidates in various stages of pre-clinical and clinical development[1].
Modelling-in-the-Loop as a New Paradigm for Quantitative Systems Pharmacology
QSP Workflow: Where Can AI Help?
State-of-the-Art on Tissue Partitioning and Volume of Distribution Predictions
Mechanistic (semi-mechanistic) methods are available to predict tissue partitioning (Kp) and Vss from compound properties and tissue physiology.
A Validation Framework for AI-Based Scientific Tools in Monolixsuite
AI tools are increasingly common in pharmacometrics, with the potential to support routine tasks and make complex workflows more efficient.
Guided Agentic Workflows for Pharmacometric Modeling Using MonolixSuite
Agentic AI can substantially accelerate pharmacometric modeling and simulation, yet its adoption depends on scientific rigor, transparency, and reproducibility.
Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin
Collaboration will apply Turin to explore mechanistic QSP model structures at scale and bring insights to development decisions where traditional modeling timelines have limited their use
AI in MIDD: From Hype to Practical Application
Everyone wants to incorporate AI into model-informed drug development (MIDD), but the open question is how to do so while maintaining scientific rigor, transparency, and regulatory confidence.
Simulations Plus Announces Completion of Acquisition by Altaris
The transaction was originally announced on June 16, 2026. At the effective time of the merger each Simulations Plus shareholder received $18.50 in cash per share. As a result of the completion of the transaction, Simulations Plus has become a privately held company, and its common stock will no longer trade on the Nasdaq Global Select Market.
Importance of Early Model Development and Data Strategy
Regulatory perspectives increasingly emphasize the value of integrating modeling early in the drug development process rather than applying it retrospectively.
Development of a PBPK Model for Mesalamine Using ACATPlus to Support Prediction of Local Gut Tissue Exposure
Mesalamine is a locally acting anti-inflammatory drug used to treat inflammatory bowel disease, where efficacy depends on achieving adequate concentrations in the terminal ileum and colonic tissues.